More Percheron Therapeutics Limited news
Percheron Therapeutics LimitedASX: PER

Orphan Drug designation from FDA for ATL1103 in Acromegaly

May 12, 2016 at 12:00 AM EDT · Issued by Percheron Therapeutics Limited

Filed with ASX · May 12, 2016 at 12:00 AM EDT · 2 pages · English

On 6ix: 6ix.com/news/orphan-drug-designation-from-fda-for-atl1103-in-acromegaly

Percheron Therapeutics Limited on 6ix

Earlier from Percheron Therapeutics

  • ATL1103 Higher Dose Study - UpdateMay 9, 2016
  • ATL1103 Deed of Settlement, Termination and TransferApr 29, 2016
  • ATL1102 for MS FDA Response to Phase IIb Study PlansMar 30, 2016
  • COR-004/ATL1103 Project UpdateMar 8, 2016
  • ATL1103 Data Presentation at Scientific ConferenceFeb 11, 2016

Later from Percheron Therapeutics

  • Company Strategy UpdateMay 23, 2016
  • Antisense Technology UpdateJun 1, 2016
  • ATL1102 for Multiple Sclerosis - UpdateJun 17, 2016
  • ATL1103 Granted Orphan Drug Designation in EuropeJun 27, 2016
  • Positive Results Achieved from ATL1103 Higher Dose StudyJul 26, 2016
All Percheron Therapeutics news releases↗

Follow Percheron Therapeutics into a list and get an email when it puts out news.

Follow Percheron Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer